Compare ResMed Inc. (RMD) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Block Inc — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Block Inc trades at $77.28 (market cap $45.20B). The key difference: Block Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Block Inc for 78 Days on average.
| RMD | XYZ | |
|---|---|---|
Market Cap | $31.89B | $45.20B |
Volume | 618,314 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $277.88 | $84.85 |
52-Week Low | $182.82 | $49.04 |
Typical Hold Time | 51 Days | 78 Days |
Enterprise Value | $31.24B | $40.10B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Block (XYZ) trades at $77.24, up 1.54% today, with strong analyst support (77% buy ratings) and a $97.47 consensus price target suggesting 26% upside. Recent quarters show earnings momentum with Q1 and Q2 2026 beats, though Q3 2026 results are pending. Revenue growth has been steady, reaching $24.19B in 2025, but net margins remain thin at 1.43%. Technical indicators are bearish overall, with the stock testing resistance near $77.
The stock offers growth potential from expanding Square and Cash App ecosystems and new banking initiatives, but faces risks from high P/E valuation (134.34), competitive pressures, and insider selling. Positive earnings surprises and institutional accumulation provide support, though profitability consistency and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
